EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)

Jesus Garcia-Donas, Laia Garrigos, Nuria Lainez, Ana Santaballa, Andres Redondo, Juan Fernando Cueva, Mª Jesus Rubio, Mario Prieto, Jose Antonio Lopez-Guerrero, Zaida Garcia-Casado, Aranzanzu Barquin, Enrique Grande und 8 weitere

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03827-4 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Jesus Garcia-Donas und 19 weiteren Autor:innen. Beteiligte Einrichtung: HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Laboratorio de Innovación en Oncología, Instituto de Investigación Sanitaria HM Hospitales…. Hauptthemen laut MEDLINE: Granulosa Cell Tumor, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Takeda Pharmaceuticals U.S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Granulosa cell ovarian tumors (GCTs) are a rare neoplasia characterized by a pathognomonic mutation in the FOXL2 gene. In vitro studies have demonstrated an overactivation of hormone activity due to this alteration. Thus, we aimed to determine the activity of orteronel, a CYP17 inhibitor, in advanced disease. METHODS: We designed a multicentric open-label phase II clinical trial. Eligible patients were adult woman with advanced or unresectable GCTs. Primary objective was clinical benefit rate, defined as the average of patients with radiological response plus stable disease longer than 6 months. RESULTS: From October 1, 2014 to May 20, 2016, ten patients were included in six participating institutions members of the GETTHI group. The study was terminated early due to a low recruitment rate. Up to 40% (CI 95% [9.6-70.4%]) cases presented a disease stabilization longer than 6 months and two of them, longer than 12 months. One patient continued on treatment at database closure 29 months after inclusion in the trial. No patient reached partial or complete response by RECIST criteria on the independent radiological review. The drug was well tolerated with nausea as the only grade 3 adverse event in one case. CONCLUSION: Low accrual led to an early interruption of the study. However, orteronel achieved a promising clinical benefit rate that supports further development of new hormonotherapies in this tumor. GOV IDENTIFIER: NCT02101684.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulosa Cell TumorOvarian NeoplasmsHumansFemaleAdultMiddle AgedAgedSteroid 17-alpha-HydroxylaseForkhead Box Protein L2

Stichwörter der Autor:innen

Clinical trialGranulosa cell ovarian tumorsGrekoOrteronel

Substanzen

Steroid 17-alpha-HydroxylaseForkhead Box Protein L2FOXL2 protein, human

Autor:innen und Institutionen

  • HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Laboratorio de Innovación en Oncología, Instituto de Investigación Sanitaria HM Hospitales, Oña Street 10, 28050, Madrid, Spain. jgarciadonas@gmail.com.
  • Hospital del Mar, Barcelona, Spain.
  • Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.
  • Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Hospital Universitario La Paz, Madrid, Spain.
  • Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.

Förderung

  • Takeda Pharmaceuticals U.S.A.

Zitieren

APA

Garcia-Donas, J., Garrigos, L., Lainez, N., Santaballa, A., Redondo, A., Cueva, J. F., Rubio, M. J., Prieto, M., Lopez-Guerrero, J. A., Garcia-Casado, Z., Barquin, A., Grande, E., Alia, E. G., Sevillano, E., Bover, I., Grazioso, T. P., Sanchez-Escribano, R., Hurtado, A., Navarro, P., & Rodriguez-Moreno, J. F. (2024). Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03827-4

Vancouver

Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, et al. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03827-4

BibTeX
@article{GarciaDonas2024,
  author = {Garcia-Donas, Jesus and Garrigos, Laia and Lainez, Nuria and Santaballa, Ana and Redondo, Andres and Cueva, Juan Fernando and Rubio, Mª Jesus and Prieto, Mario and Lopez-Guerrero, Jose Antonio and Garcia-Casado, Zaida and Barquin, Aranzanzu and Grande, Enrique and Alia, Eva Guerra and Sevillano, Elena and Bover, Isabel and Grazioso, Tatiana P and Sanchez-Escribano, Ramón and Hurtado, Alicia and Navarro, Paloma and Rodriguez-Moreno, Juan Francisco},
  title = {Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03827-4}
}
Kostenlos starten →